Relapsed Refractory Multiple Myeloma (RRMM) Latest Advances
Find the Latest Research About Relapsed Refractory Multiple Myeloma (RRMM)
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 217 publications
Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.
Journal: Cancer investigation
Published: June 21, 2026
Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.
Journal: Transplantation and cellular therapy
Published: February 12, 2026
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives.
Journal: European journal of haematology
Published: January 19, 2026
Elranatamab therapy in relapsed refractory multiple myeloma patients with chronic kidney disease: A case series.
Journal: British journal of haematology
Published: January 17, 2026
Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.
Journal: Current oncology (Toronto, Ont.)
Published: January 10, 2026
Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report.
Journal: Annals of hematology
Published: December 17, 2025
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Journal: Leukemia & lymphoma
Published: December 02, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.
Journal: Future oncology (London, England)
Published: September 15, 2025
Last Updated: 06/30/2026